Clinical Trials Directory

Trials / Completed

CompletedNCT04908761

Quadratus Lumborum Block After Living Donor Kidney Transplantation

Quadratus Lumborum Block for Analgesia After Living Donor Kidney Transplantation: A Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
88 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the postoperative analgesic effect of quadratus lumborum block in patient undergoing a living donor kidney transplant under general anesthesia.

Detailed description

The purpose of this study was to investigate whether postoperative pain is significantly reduced when TQL block was additionally performed after surgery in patients undergoing living-donor kidney transplantation. Therefore, investigator hypothesized that the analgesic consumption for postoperative 24 hours will decrease in TQL group compared to the control group. For secondary outcomes, the pain score at rest/ movement up to 48 hours after surgery, the time until the first pain reliever is requested, whether and how often rescue analgesics are administered for 48 hours, the incidence and severity of nausea and vomiting during the 48 hours after surgery, patient's satisfaction with post-pain control and the number of hospital stays were investigated. Overall, the aim of this study is to evaluate the postoperative analgesic effect of quadratus lumborum block in patients undergoing a living donor kidney transplantation under general anesthesia.

Conditions

Interventions

TypeNameDescription
PROCEDURETransmuscular quadratus lumborum blockPatients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
PROCEDUREPlaceboFor patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block.

Timeline

Start date
2021-06-03
Primary completion
2022-05-18
Completion
2022-05-28
First posted
2021-06-01
Last updated
2022-12-27

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04908761. Inclusion in this directory is not an endorsement.